
Amplion: A leading healthcare tech provider, innovating in patient-care communication since 1979.
Amplion Clinical Communications, originally founded as Dalcon Communications in 1979 and headquartered in Nashville, specializes in developing and implementing patient-care communication technology for hospitals and health systems. The company's core mission is to enhance patient care through innovative communication solutions. Amplion offers a range of products and services, including VoIP unified communications software and unified patient-care communication systems, focusing on improving the efficiency and effectiveness of healthcare delivery.
Notable affiliated individuals include key industry experts and seasoned professionals in healthcare technology. Amplion has attracted significant investment from prominent venture capital firms, bolstering its growth and innovation capabilities. Key achievements include pioneering multi-user microcomputer-based systems in the early 1980s and advancing to VoIP technologies by 2006. Amplion's impact is evident in its long-standing reputation for technological excellence and its contribution to improving patient-care communication in healthcare settings.

Eloquence Communications

Amptify
amptify.com

AmplifyMD
amplifymd.com

Patient Communicator

VocoMD

Twiage
twiagemed.com

Vital Interaction

Healthcall
healthcall.com

WellBeam
well-beam.com

RxVantage
rxvantage.com

Voxello
voxello.com

Playback Health
playbackhealth.com

Caremesh
caremesh.com

MedChat
medchatapp.com

Commure
commure.com
Companies similar to Amplion Clinical Communications include Eloquence Communications, Amptify, AmplifyMD and Patient Communicator.
Amplion Clinical Communications was founded in 1987.
Amplion Clinical Communications' headquarters is located in Nashville, TN, US.
Amplion Clinical Communications' most recent funding round was for $3M (USD) in September 2013.
As of Sep 1, 2013, Amplion Clinical Communications has raised a total of $6.8M (USD).
Amplion Clinical Communications has 32 employees as of Feb 4, 2024.